V. Craig Jordan focuses on Internal medicine, Tamoxifen, Breast cancer, Estrogen receptor and Antiestrogen. His study in Internal medicine is interdisciplinary in nature, drawing from both Regulation of gene expression, Endocrinology, Oncology and Transfection. The Tamoxifen study combines topics in areas such as Aromatase and Pharmacology.
The concepts of his Breast cancer study are interwoven with issues in Uterine cancer, Gynecology, Endometrial cancer and Adjuvant therapy. His Estrogen receptor study combines topics from a wide range of disciplines, such as Receptor, Transcription factor, Estrogen and Molecular biology. His research integrates issues of Metabolite, Bone density, Ovariectomized rat and Chemotherapy in his study of Antiestrogen.
His primary areas of investigation include Internal medicine, Tamoxifen, Breast cancer, Estrogen receptor and Endocrinology. His Internal medicine study frequently intersects with other fields, such as Oncology. His Tamoxifen research includes themes of Aromatase, Chemotherapy and Pharmacology.
His Breast cancer research incorporates elements of Gynecology, Osteoporosis and Adjuvant therapy. His Estrogen receptor research is multidisciplinary, incorporating elements of Receptor and Cancer research. His Endocrinology study combines topics in areas such as Progesterone receptor and Toremifene.
V. Craig Jordan spends much of his time researching Internal medicine, Breast cancer, Tamoxifen, Oncology and Estrogen. His Internal medicine study often links to related topics such as Endocrinology. To a larger extent, he studies Cancer with the aim of understanding Breast cancer.
In his work, Bioinformatics is strongly intertwined with Pharmacology, which is a subfield of Tamoxifen. He has included themes like Apoptosis and Estrogen receptor in his Estrogen study. His Estrogen receptor research incorporates themes from Receptor and Cancer research.
Tamoxifen, Breast cancer, Estrogen receptor, Internal medicine and Oncology are his primary areas of study. In his research, Hormone replacement therapy, Bioinformatics and Lasofoxifene is intimately related to Pharmacology, which falls under the overarching field of Tamoxifen. As part of one scientific family, V. Craig Jordan deals mainly with the area of Breast cancer, narrowing it down to issues related to the Estrogen, and often Apoptosis and Molecular biology.
The various areas that V. Craig Jordan examines in his Estrogen receptor study include Cancer research and Targeted therapy. His study ties his expertise on Endocrinology together with the subject of Internal medicine. His Selective estrogen receptor modulator research is multidisciplinary, incorporating perspectives in Antiestrogen and Angiogenesis inhibitor.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results From the MORE Randomized Trial
Steven R. Cummings;Stephen Eckert;Kathryn A. Krueger;Deborah Grady.
Tamoxifen: a most unlikely pioneering medicine.
V. Craig Jordan.
Nature Reviews Drug Discovery (2003)
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
Victor G. Vogel;Joseph P. Costantino;D. Lawrence Wickerham;D. Lawrence Wickerham;Walter M. Cronin.
Basic Guide to the Mechanisms of Antiestrogen Action
Jennifer I. Macgregor;V. Craig Jordan.
Pharmacological Reviews (1998)
International Union of Pharmacology. LXIV. Estrogen Receptors
Karin Dahlman-Wright;Vincent Cavailles;Suzanne A. Fuqua;V. Craig Jordan.
Pharmacological Reviews (2006)
Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer
Victor G. Vogel;Victor G. Vogel;Joseph P. Costantino;D. Lawrence Wickerham;Walter M. Cronin.
Cancer Prevention Research (2010)
MCF-7: The First Hormone-responsive Breast Cancer Cell Line
Anait S. Levenson;V. Craig Jordan.
Cancer Research (1997)
Development of Antiestrogens and Their Use in Breast Cancer: Eighth Cain Memorial Award Lecture
Leonard J. Lerner;V. Craig Jordan.
Cancer Research (1990)
The estrogen receptor: A model for molecular medicine
Elwood V. Jensen;V. Craig Jordan.
Clinical Cancer Research (2003)
Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions.
V. Craig Jordan.
Journal of Medicinal Chemistry (2003)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: